导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.92% | 1151/4773 |
| 近一周 | -2.54% | 2502/5462 |
| 近一月 | -4.48% | 2503/5421 |
| 近一季 | -6.89% | 2228/5209 |
| 近半年 | -3.52% | 2231/4920 |
| 近一年 | 10.03% | 1036/4366 |
| 近两年 | 81.64% | 786/2954 |
| 近三年 | 49.19% | 549/2253 |
| 成立以来 | 125.31% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.80% 1442/4961 |
19.89% 1269/5312 |
- - |
- - |
| 2025 | 36.33% 953/4813 |
4.42% 938/3635 |
2.83% 1322/4076 |
25.14% 1413/4524 |
1.47% 1367/4813 |
| 2024 | 8.94% 1502/3463 |
-1.26% 1206/2808 |
-3.87% 1427/3014 |
14.25% 2022/3129 |
0.46% 1207/3463 |
| 2023 | -5.97% 799/2656 |
4.41% 961/2280 |
-2.88% 701/2385 |
-3.24% 878/2515 |
-4.16% 896/2655 |
| 2022 | -16.39% 475/2207 |
-10.99% 467/1919 |
3.41% 1158/2016 |
-10.34% 385/2113 |
1.32% 1309/2208 |
| 2021 | 25.47% 109/1822 |
1.88% 238/1255 |
9.76% 524/1330 |
7.48% 184/1466 |
4.40% 334/1822 |
| 2020 | 40.14% 316/1250 |
-1.34% 214/1028 |
19.13% 310/1067 |
13.35% 325/1164 |
5.19% 799/1184 |
| 2019 | 32.83% 441/1092 |
29.42% 278/739 |
-6.41% 502/788 |
1.23% 423/850 |
8.33% 326/918 |
| 2018 | -25.62% 358/834 |
- - |
-11.16% 350/631 |
-7.26% 442/660 |
-9.82% 166/682 |
| 2017 | 7.64% 316/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中金中证500C VS. 长安沪深300非周期A(740101) |